Cargando…
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases()
Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggr...
Autores principales: | Flørenes, Vivi Ann, Flem-Karlsen, Karine, McFadden, Erin, Bergheim, Inger Riise, Nygaard, Vigdis, Nygård, Vegard, Farstad, Inger Nina, Øy, Geir Frode, Emilsen, Elisabeth, Giller-Fleten, Karianne, Ree, Anne Hansen, Flatmark, Kjersti, Gullestad, Hans Petter, Hermann, Robert, Ryder, Truls, Wernhoff, Patrik, Mælandsmo, Gunhild Mari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520638/ https://www.ncbi.nlm.nih.gov/pubmed/31096111 http://dx.doi.org/10.1016/j.tranon.2019.04.001 |
Ejemplares similares
-
Soluble AXL as a marker of disease progression and survival in melanoma
por: Flem-Karlsen, Karine, et al.
Publicado: (2020) -
AXL inhibition improves BRAF-targeted treatment in melanoma
por: Nyakas, Marta, et al.
Publicado: (2022) -
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
por: Magnussen, Gry Irene, et al.
Publicado: (2015) -
hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
por: Fleten, Karianne G, et al.
Publicado: (2016) -
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
por: Slipicevic, Ana, et al.
Publicado: (2012)